Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling-Reference-Cited by-同舟云学术

Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling

Published:2020-07-22 Issue:8 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Rajoli Rajith K. R.¹^ORCID,Demkovich Zach R.²,Flexner Charles³,Owen Andrew¹,Siccardi Marco¹

Affiliation:

1. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom

2. RTI International, Durham, North Carolina, USA

3. Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, Maryland, USA

Abstract

Long-acting (LA) administration using a subcutaneous (s.c.) implant presents opportunities to simplify administration of antiretroviral drugs, improve pharmacological profiles, and overcome suboptimal adherence associated with daily oral formulations. Tenofovir alafenamide (TAF) is a highly potent nucleoside reverse transcriptase inhibitor (NRTI) and an attractive agent for LA delivery, with a high potency and long intracellular half-life. The aim of this study was to predict minimum TAF doses required to achieve concentrations effective for HIV preexposure prophylaxis (PrEP).

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00155-20

Reference44 articles.

1. UNAIDS. 2019. Global HIV & AIDS statistics—2019 fact sheet. http://www.unaids.org/en/resources/fact-sheet. Accessed 1 February 2018.

2. UNAIDS. 2018. The youth bulge and HIV. https://www.unaids.org/sites/default/files/media_asset/the-youth-bulge-and-hiv_en.pdf. Accessed 21 January 2020.

3. Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game?

4. The Effect of PrEP on HIV Incidence Among Men Who Have Sex With Men in the Context of Condom Use, Treatment as Prevention, and Seroadaptive Practices

5. How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP;Pilkington V;J Virus Erad,2018

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Pharmacokinetics of a BCS Class III Drug with Two Different Study Designs: Tenofovir Alafenamide Monofumarate Film-coated Tablet;AAPS PharmSciTech;2024-05-30

2. Role of Modeling and Simulation in Preclinical and Clinical Long-Acting Injectable Drug Development;The AAPS Journal;2023-10-17

3. Revisiting the in-vitro and in-vivo considerations for in-silico modelling of complex injectable drug products;Journal of Controlled Release;2023-08

4. A Perspective on Model-Informed IVIVC for Development of Subcutaneous Injectables;Pharmaceutical Research;2023-07

5. Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records;Antimicrobial Agents and Chemotherapy;2023-05-17